Dr. Deshpande joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President Research and Development in October 2010. In May 2013, Dr. Deshpande was appointed President and Chief Executive Officer of Achillion and joined the Board of Directors.
Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.
Achillion stock has gained 273% this year on the back of strong results for its HCV drug trial for ACH-3102
ABOUT THE CEO BREAKFAST CLUB
The NewYorkBIO CEO Breakfast Club is an intimate, bi-monthly breakfast and networking event headlined by some of New York’s leading life science entrepreneurs and investors.
Limited to 25 attendees, the Breakfast Club is restricted to life science executives (no service providers beyond the sponsor) and will offer a unique opportunity to hear directly from-and to network with—New York’s life science leadership.
Agenda: 7:30-8:15 am Registration, Networking and Breakfast
8:15-9:15 am Speaker Program
9:15-9:30 am Q&A and closing
PLEASE NOTE: Attendance to CEO Breakfast Club events is restricted to C-level life science executives--registrations from service providers and vendors will be respectfully declined. NewYorkBIO members receive priority seating.
Have questions about CEO Breakfast Club with Milind Deshpande, CEO, Achillion?